Custom Protein Generation

Drug Substance Manufacture

Drug Product Fill & Finish

Development

Testing

Discovery

Antibody Drug Conjugates

Technologies & Platforms

2018/12/19
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

2018/12/13
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

2018/12/12
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

2018/12/11
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

2018/12/10
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

2018/12/06
WuXi Biologics Wins SCRIP Award for “Best Company in an Emerging Market”

2018/12/05
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

2018/11/29
WuXi Biologics Selected as Forbes Asia’s Best Under A Billion 2018

2018/11/28
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

2018/11/22
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai

2018/11/07
WuXi Biologics’ Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting

2018/10/31
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang

2018/10/29
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed

2018/10/23
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics

2018/09/26
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

2018/09/25
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board

2018/09/18
WuXi Biologics’ Chief Quality Officer Received Foreign Post Service Award from FDA

2018/09/11
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing

2018/08/30
WuXi Biologics Selected into the Hang Seng HK 35 Index

2018/08/20
WuXi Biologics Reports Robust 2018 Interim Results

2018/07/31
WuXi Biologics Commenced Process Validation in MFG2

2018/07/25
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3

2018/07/09
WuXi Biologics and Immune Pharmaceuticals Announce Late-Phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody

2018/06/25
WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership

2018/06/20
WuXi Biologics Initiated Construction of a State-of-the-Art Integrated ADC Solution Center

2018/06/11
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States

2018/05/30
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership

2018/05/22
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore

2018/05/21
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis’ Lead Investigational Candidate to Treat Brain Cancer

2018/05/16
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

2018/05/14
WuXi Biologics Congratulates Aravive Biologics on Achieving Proof-of-Mechanism for Novel Biologic AVB-S6-500 within 20 Months from Cell Line Development

2018/04/30
WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

2018/04/17
WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

2018/03/21
WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

2018/03/19
WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million

2018/03/09
WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership

2018/03/07
WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo

2018/03/06
WuXi Biologics Receives Asia’s CMO of 2017 from BioPharma Industry Awards

2018/03/05
WuXi Biologics Announces Positive Profit Alert

2018/02/27
WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311

2018/02/13
WuXi Biologics Receives Two Bioprocessing Awards from IMAPAC

2018/02/09
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

2018/01/31
WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

2018/01/30
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

2018/01/24
WuXi Biologics Announces Formation of Scientific Advisory Board

2018/01/15
WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer

2018/01/09
WuXi Biologics Receives Best IPO Award and Best Investor Relations Award 2017

 

See below for other press releases by year.

2018  2017  2016  2015  2014  2013  2012

BACK